Laigo Bio is pioneering a targeted membrane protein degradation platform to address oncology, autoimmune, and inflammatory disorders
Laigo Bio is pioneering a targeted membrane protein degradation platform to address oncology, autoimmune, and inflammatory disorders. Their proprietary SureTAC™ product uniquely leverages the proximity between E3 ligases and specific targets, inducing ubiquitination and subsequent lysosomal degradation.